Clinical trials: Resistant Depression, Treatment
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Depressive Disorder, Treatment-Resistant
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
This study evaluates the efficacy and safety of ethosuximide in the treatment of refractory depressive disorder in adults. Half of participants will receive ethosuximide and escitalopram in combination, while the other half will…
- Trial name
- NCT03887624
- Testing
- Ethosuximide, Escitalopram
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang University
Bipolar Disorder, Bipolar Depression
Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression
Growing evidence has supported rapid and robust antidepressant effects with subanesthetic doses of intravenous (IV) ketamine for treatment resistant depression (TRD).
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- KET-BD-Sustain (NCT05339074)
- Testing
- Ketamine Hydrochloride
- Where
- 3 sites in Canada
- Volunteers
- 41 people
- Sponsor
- Joshua Rosenblat
Depressive Disorder, Treatment-Resistant
Personalized rTMS for Resistant Depression
The investigators hypothesize that personalizing the rTMS targets using functional MRI will increase its efficacy. The most dysfunctional regions or the most dysfunctional network will be stimulated homogeneously.
- Trial name
- NCT02863380
- Testing
- Functional magnetic resonance imaging used to individualize rTMS protocol, Individualized rTMS (transcranial magnetic stimulation), Classical rTMS (transcranial magnetic stimulation)
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Strasbourg, France
Treatment of Resistant Depression, H1-Coil
Theta Burst Stimulation With an 8-Coil Versus H1-Coil for Resistant Depression
The goal of this clinical trial is to compare response rates after treatment with Figure Eight-Coil TMS versus H-Coil TMS on the prefrontal cortex left dorsolateral, in patients suffering from depression resistant.
- Conditions
- Treatment of Resistant Depression, H1-Coil, Theta Burst Stimulation
- Trial name
- rTBShTBS (NCT06813313)
- Testing
- repetitive transcranial magnetic stimulation
- Volunteers
- 108 people
- Sponsor
- Dominique JANUEL
Therapy Resistant Major Depression
Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression
tDCS applies a small amount of direct electric current (DC) to the brain by means of two electrodes: the one is an active electrode, localized on the effective site, and the other is a reference electrode, localized on some…
- Trial name
- NCT00667680
- Testing
- Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Treatment Resistant Major Depressive Disorder
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD).
- Trial name
- STRIDE-1 (NCT02741791)
- Testing
- AXS-05, Bupropion
- Where
- 74 sites in United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression, Depressive Disorder
Buprenorphine for Treatment Resistant Depression
The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- BUP-TRD (NCT01407575)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD).
- Trial name
- NCT07053345
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 6 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- Janssen Korea, Ltd., Korea
Persistent Depressive Disorder, Treatment-resistant Depression
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
The purpose of this study is to compare the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) conducted over 16 weeks (acute and continuation treatment) with Behavioral Activation (BA; same dose and duration) in…
- Trial name
- ChangePDD (NCT04996433)
- Testing
- inpatient CBASP individual therapy, inpatient CBASP group therapy, inpatient CBASP nurse contact
- Where
- 8 sites in Germany
- Volunteers
- 396 people
- Sponsor
- University of Greifswald
Depression, Treatment Resistant Depression
Mindfulness Engaged Neurostimulation for Depression
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region.
- Conditions
- Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
- Trial name
- MEND I (NCT06399406)
- Testing
- Medi-TBS
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Diego
Depressive Episode, Electroconvulsive Therapy
Electroconvulsive Treatment Followed by Cognitive Control Training
Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high.
- Conditions
- Depressive Episode, Electroconvulsive Therapy, Cognitive Remediation
- Trial name
- ECT-CCT (NCT04383509)
- Testing
- Cognitive Control Training, Active Control
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- University Ghent
Treatment Resistant Depression (TRD)
Maintenance TMS in Treatment Resistant Depression
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use.
- Trial name
- NCT06682299
- Testing
- Transmagnetic Stimulation, Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Austin Messner
Treatment Resistant Depression, Major Depressive Disorder
Predictors of Intravenous Ketamine Response in TRD
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT05625555
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abraham Nunes
Depression Chronic, Depression, Unipolar
Psychotherapeutic Augmentation of Brain Stimulation Effects
This study aims to investigate effectiveness and feasability of a 15-week group psychotherapeutic intervention as continuation treatment after electroconvulsive therapy in severely depressed patients.
- Conditions
- Depression Chronic, Depression, Unipolar, Treatment Resistant Depression
- Trial name
- PAUSE (NCT04159285)
- Testing
- EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients, Treatment as usual
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Charite University, Berlin, Germany
Refractory Depression, Treatment Resistant Depression
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: Does psilocybin with assisted therapy help improve…
- Trial name
- NCT06303739
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic
The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose aiTBS protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with unipolar…
- Trial name
- NCT04384965
- Testing
- MagPro X100 Stimulator, B70 Fluid-Cooled Coil
- Where
- Canada
- Volunteers
- 176 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Treatment Resistant Depression
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression
This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual.
- Trial name
- NCT07528157
- Testing
- Personalized iTBS, Non-Personalized iTBS
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Stanford University